Yamaguchi K, Takao S, Kanaji N, Hirakawa T, et al. The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004). Eur J Cancer 2025;226:115606.
PMID: 40639019